Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc.: Corporate Update

V.HEM

CALGARY, ALBERTA--(Marketwired - Jan. 12, 2015) - Hemostemix Inc. (the "Corporation") (TSX VENTURE:HEM) announces Dr. Valentin Fulga, is leaving the company's management team where he was President, effective immediately. Dr. Fulga will continue to serve as a director.

About Hemostemix

Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol "HEM".

Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) has in any way passed upon the merits of this news release and has neither approved nor disapproved of the contents of this press release. 

Hemostemix Inc.
Dr. Elmar Burchardt
CEO
(617) 500-8401

Hemostemix Inc.
C.W. (Bill) Baker
Chairman of the Board
(403) 818-7672



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today